Literature DB >> 28367259

United States Food and Drug Administration Product Label Changes.

Leon Kircik1, Julie C Sung2, Linda Stein-Gold3, Gary Goldenberg2.   

Abstract

Once a drug has been approved by the United States Food and Drug Administration and is on the market, the Food and Drug Administration communicates new safety information through product label changes. Most of these label changes occur after a spontaneous report to either the drug manufacturing companies or the Food and Drug Administration MedWatch program. As a result, 400 to 500 label changes occur every year. Actinic keratosis treatments exemplify the commonality of label changes throughout the postmarket course of a drug. Diclofenac gel, 5-fluorouracil cream, imiquimod, and ingenol mebutate are examples of actinic keratosis treatments that have all undergone at least one label revision. With the current system of spontaneous reports leading to numerous label changes, each occurrence does not necessarily signify a radical change in the safety of a drug.

Entities:  

Year:  2017        PMID: 28367259      PMCID: PMC5367870     

Source DB:  PubMed          Journal:  J Clin Aesthet Dermatol        ISSN: 1941-2789


  6 in total

1.  The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction.

Authors:  Richard Platt; Ryan M Carnahan; Jeffrey S Brown; Elizabeth Chrischilles; Lesley H Curtis; Sean Hennessy; Jennifer C Nelson; Judith A Racoosin; Melissa Robb; Sebastian Schneeweiss; Sengwee Toh; Mark G Weiner
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-01       Impact factor: 2.890

2.  The US Food and Drug Administration's Sentinel Initiative: expanding the horizons of medical product safety.

Authors:  Melissa A Robb; Judith A Racoosin; Rachel E Sherman; Thomas P Gross; Robert Ball; Marsha E Reichman; Karen Midthun; Janet Woodcock
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-01       Impact factor: 2.890

Review 3.  Role of postmarketing surveillance in contemporary medicine.

Authors:  Janet Woodcock; Rachel E Behrman; Gerald J Dal Pan
Journal:  Annu Rev Med       Date:  2011       Impact factor: 13.739

4.  Post-market drug safety evidence sources: an analysis of FDA drug safety communications.

Authors:  Chieko Ishiguro; Marni Hall; George A Neyarapally; Gerald Dal Pan
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-10       Impact factor: 2.890

5.  Evaluation of FDA safety-related drug label changes in 2010.

Authors:  Jean Lester; George A Neyarapally; Earlene Lipowski; Cheryl Fossum Graham; Marni Hall; Gerald Dal Pan
Journal:  Pharmacoepidemiol Drug Saf       Date:  2013-01-02       Impact factor: 2.890

Review 6.  A comparison of active adverse event surveillance systems worldwide.

Authors:  Yu-Lin Huang; Jinhee Moon; Jodi B Segal
Journal:  Drug Saf       Date:  2014-08       Impact factor: 5.606

  6 in total
  1 in total

Review 1.  Pharmacovigilance: reporting requirements throughout a product's lifecycle.

Authors:  Sylvia Lucas; Jessica Ailani; Timothy R Smith; Ahmad Abdrabboh; Fei Xue; Marco S Navetta
Journal:  Ther Adv Drug Saf       Date:  2022-09-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.